Table 2 Association between p-Smad2 expression in cancer cells or stromal fibroblasts and clinicopathologic characteristics
p-Smad2 expression in cancer cells | p-Smad2 expression in stromal fibroblasts | ||||||
|---|---|---|---|---|---|---|---|
Variables | Number of patients | Low (%) | High (%) | P | Low (%) | High (%) | P |
Gender | |||||||
Male | 55 | 5 (9.1) | 50 (90.9) | 0.473 | 32 (58.2) | 23 (41.8) | 0.346 |
Female | 23 | 1 (4.3) | 22 (95.7) | 16 (69.6) | 7 (30.4) | ||
Age (years) | |||||||
≤63 | 41 | 2 (4.9) | 39 (95.1) | 0.326 | 23 (56.1) | 18 (43.9) | 0.298 |
>63 | 37 | 4 (10.8) | 33 (89.2) | 25 (67.6) | 12 (32.4) | ||
Pathologic type | |||||||
Squamous carcinoma | 41 | 2 (4.9) | 39 (95.1) | 0.560 | 24 (58.5) | 17 (41.5) | 0.605 |
Adenocarcinoma | 29 | 3 (10.3) | 26 (89.7) | 20 (69.0) | 9 (31.0) | ||
Adenosquamous carcinoma | 3 | 0 (0) | 3 (100.0) | 2 (66.7) | 1 (33.3) | ||
Large cell carcinoma | 5 | 1 (20.0) | 4 (80.0) | 2 (40.0) | 3 (60.0) | ||
Pathologic differentiation | |||||||
High | 5 | 0 (0) | 5 (100.0) | 0.562 | 4 (80.0) | 1 (20.0) | 0.679 |
Median | 50 | 5 (10.0) | 45 (90.0) | 30 (60.0) | 20 (40.0) | ||
Low | 23 | 1 (4.3) | 22 (95.7) | 14 (60.9) | 9 (39.1) | ||
Clinical Stage* | |||||||
I + II | 29 | 4 (13.8) | 25 (86.2) | 0.120 | 20 (69.0) | 9 (31.0) | 0.300 |
IIIA | 49 | 2 (4.1) | 47 (95.9) | 28 (57.1) | 21(42.9) | ||